Related Experiment Videos
Fluorescein dilaurate test of exocrine pancreatic function in cystic fibrosis
1Royal Liverpool, Children's Hospital, Alder Hey, Liverpool.
Archives of Disease in Childhood
|July 1, 1990
Insights
The fluorescein dilaurate test accurately identifies pancreatic exocrine insufficiency in children with cystic fibrosis. This non-invasive method effectively distinguishes patients from healthy individuals.
Area of Science:
- Pediatric Gastroenterology
- Pancreatic Physiology
- Diagnostic Testing
Background:
- Cystic fibrosis (CF) frequently causes pancreatic exocrine insufficiency.
- Accurate assessment of exocrine pancreatic function is crucial for CF management.
- Non-invasive diagnostic methods are preferred for pediatric patients.
Purpose of the Study:
- To evaluate the efficacy of the fluorescein dilaurate test in diagnosing pancreatic exocrine insufficiency in children with CF.
- To determine if the fluorescein dilaurate test can differentiate CF patients with insufficiency from healthy controls.
Main Methods:
- The fluorescein dilaurate test was performed on 21 children diagnosed with cystic fibrosis and pancreatic exocrine insufficiency.
- A control group of 12 healthy siblings was included for comparison.
- The test measures exocrine pancreatic function non-invasively.
Main Results:
- The fluorescein dilaurate test demonstrated clear discrimination between the two groups.
- Patients with cystic fibrosis and severe pancreatic exocrine insufficiency showed significantly different results compared to healthy controls.
Conclusions:
- The fluorescein dilaurate test is a reliable, non-invasive tool for assessing exocrine pancreatic function in children with cystic fibrosis.
- This test effectively distinguishes pediatric CF patients with pancreatic insufficiency from healthy individuals, aiding in diagnosis and management.
Abstract:
The fluorescein dilaurate test, a non-invasive test of exocrine pancreatic function, was carried out on 21 children with cystic fibrosis and pancreatic exocrine insufficiency, and 12 healthy siblings. The test clearly discriminated between the patients with cystic fibrosis and severe exocrine pancreatic insufficiency and the normal control subjects.